Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Eur Respir J
; 59(2)2022 02.
Article
in English
| MEDLINE | ID: covidwho-1376571
ABSTRACT
BACKGROUND:
Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness.METHODS:
In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4â units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT50)) ≥1/320 was the product of choice for the study.RESULTS:
Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 21 allocation scheme. A median (interquartile range) volume of 884 (806-906)â mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7â days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59-1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%).CONCLUSIONS:
Transfusion of 4â units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunization, Passive
/
COVID-19
/
Antibodies, Viral
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Adult
/
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
13993003.01724-2021
Similar
MEDLINE
...
LILACS
LIS